Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of DA-1229_01(A) vs Sugamet SR in Healthy Adults
NCT03939143Phase 1Completed
- Sponsor
- Dong-A ST
- Start
- Feb 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DA5221-B2 and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Dong-A ST. Primary endpoints: Area under the concentration-time curve (AUCt) and Maximum plasma concentration (Cmax). Started Feb 2019; status: completed.
02
Drugs
DA5221-B2liquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03939143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03939143.